Company profile
Ticker
TVTX
Exchange
Website
CEO
Dr. Eric M. Dube Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Desert Gateway, Inc., Retrophin, Inc.
SEC CIK
Corporate docs
Subsidiaries
Travere Therapeutics Pharmaceutical, Inc. • Travere Therapeutics Ireland Limited • Travere Therapeutics Switzerland GmbH • Kyalin Biosciences, Inc. • Manchester Pharmaceuticals LLC ...
IRS number
262383102
TVTX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
8-K
Travere Therapeutics Provides Corporate Update and 2025 Outlook
13 Jan 25
8-K
Travere Therapeutics Announces Proposed Public Offering of Common Stock
8 Nov 24
424B5
Prospectus supplement for primary offering
8 Nov 24
424B5
Prospectus supplement for primary offering
7 Nov 24
424B5
Prospectus supplement for primary offering
31 Oct 24
10-Q
2024 Q3
Quarterly report
31 Oct 24
8-K
Travere Therapeutics Reports Third Quarter 2024 Financial Results
31 Oct 24
8-K
Other Events
26 Sep 24
8-K
Other Events
5 Sep 24
S-3ASR
Automatic shelf registration
1 Aug 24
Transcripts
TVTX
Earnings call transcript
2024 Q3
31 Oct 24
TVTX
Earnings call transcript
2024 Q2
1 Aug 24
TVTX
Earnings call transcript
2024 Q1
6 May 24
TVTX
Earnings call transcript
2023 Q4
15 Feb 24
TVTX
Earnings call transcript
2023 Q3
7 Nov 23
TVTX
Earnings call transcript
2023 Q2
3 Aug 23
TVTX
Earnings call transcript
2023 Q2
3 Aug 23
TVTX
Earnings call transcript
2023 Q1
4 May 23
TVTX
Earnings call transcript
2022 Q4
23 Feb 23
TVTX
Earnings call transcript
2022 Q3
28 Oct 22
Latest ownership filings
4
WILLIAM E. ROTE
23 Jan 25
4
Eric M Dube
23 Jan 25
4
ELIZABETH E REED
23 Jan 25
4
Roy D. Baynes
23 Jan 25
4
Peter Heerma
23 Jan 25
4
Christopher R. Cline
23 Jan 25
4
Sandra Calvin
23 Jan 25
144
Notice of proposed sale of securities
23 Jan 25
144
Notice of proposed sale of securities
22 Jan 25
144
Notice of proposed sale of securities
22 Jan 25
Financial summary
Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | |||
---|---|---|---|---|---|---|
Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q | |
Cash on hand (at last report) | 36.41 mm | 36.41 mm | 36.41 mm | 36.41 mm | 36.41 mm | 36.41 mm |
Cash burn (monthly) | (no burn) | 8.99 mm | 18.72 mm | 29.93 mm | 14.17 mm | 22.69 mm |
Cash used (since last report) | n/a | 35.78 mm | 74.52 mm | 119.17 mm | 56.41 mm | 90.32 mm |
Cash remaining | n/a | 631.42 k | -38.11 mm | -82.76 mm | -20.00 mm | -53.91 mm |
Runway (months of cash) | n/a | 0.1 | -2.0 | -2.8 | -1.4 | -2.4 |
Institutional ownership, Q3 2024
22.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 7 |
Opened positions | 0 |
Closed positions | 166 |
Increased positions | 2 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 373.50 mm |
Total shares | 19.46 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 7.65 mm | $135.83 mm |
Woodline Partners | 4.34 mm | $77.08 mm |
STT State Street | 2.74 mm | $49.10 mm |
MFC Manulife Financial | 2.16 mm | $58.79 mm |
MS Morgan Stanley | 1.32 mm | $23.44 mm |
Integrated Core Strategies | 727.18 k | $19.82 mm |
Deep Track Capital | 531.86 k | $9.45 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Jan 25 | Baynes Roy D. | Common Stock | Sell | Dispose S | No | Yes | 20 | 16,000 | 320.00 k | 31,000 |
23 Jan 25 | Baynes Roy D. | Common Stock | Option exercise | Acquire M | No | No | 17.5 | 16,000 | 280.00 k | 47,000 |
23 Jan 25 | Baynes Roy D. | Stock option Common Stock | Option exercise | Dispose M | No | No | 17.5 | 16,000 | 280.00 k | 0 |
22 Jan 25 | Sandra Calvin | Common Stock | Sell | Dispose S | No | No | 18.9408 | 925 | 17.52 k | 54,002 |
22 Jan 25 | Christopher R. Cline | Common Stock | Sell | Dispose S | No | No | 18.9409 | 865 | 16.38 k | 73,730 |
22 Jan 25 | Peter Heerma | Common Stock | Sell | Dispose S | No | No | 18.9408 | 1,584 | 30.00 k | 106,374 |
22 Jan 25 | Reed Elizabeth E | Common Stock | Sell | Dispose S | No | Yes | 19.46 | 2,437 | 47.42 k | 76,933 |
News
HC Wainwright & Co. Maintains Buy on Travere Therapeutics, Raises Price Target to $22
1w ago
Travere Therapeutics Expects Q4 Net Product Sales To Be $74M;
2w ago
Piper Sandler Maintains Neutral on Travere Therapeutics, Raises Price Target to $22
2mo ago
Scotiabank Maintains Sector Outperform on Travere Therapeutics, Raises Price Target to $27
2mo ago
Barclays Maintains Overweight on Travere Therapeutics, Raises Price Target to $20
2mo ago
Press releases
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
3w ago
Travere Therapeutics to Present at Upcoming Investor Conferences
2mo ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
2mo ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2mo ago
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares
2mo ago